Gene · 6080
Papers2,015
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
161 to 180 of 2,015
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Plasma SNORD42B and SNORD111 as potential biomarkers for early diagnosis of non-small cell lung cancer. | J Clin Lab Anal | 2022 | 36284435 | PubTator, text mining | PubMed |
| Analysis and comparison of anti-RBD neutralizing antibodies from AZD-1222, Sputnik V, Sinopharm and Covaxin vaccines and its relationship with gender among health care workers. | Immun Ageing | 2022 | 36273175 | PubTator, text mining | PubMed |
| Improving cancer immunotherapy by rationally combining oncolytic virus with modulators targeting key signaling pathways. | Mol Cancer | 2022 | 36221123 | PubTator, text mining | PubMed |
| Oncolytic virus-mediated p53 overexpression promotes immunogenic cell death and efficacy of PD-1 blockade in pancreatic cancer. | Mol Ther Oncolytics | 2022 | 36212775 | PubTator, text mining | PubMed |
| Crosstalk between the Intestinal Virome and Other Components of the Microbiota, and Its Effect on Intestinal Mucosal Response and Diseases. | J Immunol Res | 2022 | 36203793 | PubTator, text mining | PubMed |
| Engineering Cancer Selective Virotherapies: Are the Pieces of the Puzzle Falling into Place? | Hum Gene Ther | 2022 | 36178346 | PubTator, text mining | PubMed |
| Glioblastoma microenvironment and its reprogramming by oncolytic virotherapy. | Front Cell Neurosci | 2022 | 36159398 | PubTator, text mining | PubMed |
| Recent Advances in Glioma Cancer Treatment: Conventional and Epigenetic Realms. | Vaccines (Basel) | 2022 | 36146527 | PubTator, text mining | PubMed |
| Strategies for Advanced Oncolytic Virotherapy: Current Technology Innovations and Clinical Approaches. | Pharmaceutics | 2022 | 36145559 | PubTator, text mining | PubMed |
| P16INK4A-More Than a Senescence Marker. | Life (Basel) | 2022 | 36143369 | PubTator, text mining | PubMed |
| Recombinant Viral Vectors for Therapeutic Programming of Tumour Microenvironment: Advantages and Limitations. | Biomedicines | 2022 | 36140243 | PubTator, text mining | PubMed |
| Hsa-microRNA-27b-3p inhibits hepatocellular carcinoma progression by inactivating transforming growth factor-activated kinase-binding protein 3/nuclear factor kappa B signalling. | Cell Mol Biol Lett | 2022 | 36138344 | PubTator, text mining | PubMed |
| Hsp90 Inhibitor STA9090 induced VPS35 related extracellular vesicle release and metastasis in hepatocellular carcinoma. | Transl Oncol | 2022 | 36137350 | PubTator, text mining | PubMed |
| Systematic Review of Pediatric Brain Tumors in Neurofibromatosis Type 1: Status of Gene Therapy. | Cureus | 2022 | 36120213 | PubTator, text mining | PubMed |
| Novel viral splicing events and open reading frames revealed by long-read direct RNA sequencing of adenovirus transcripts. | PLoS Pathog | 2022 | 36095031 | PubTator, text mining | PubMed |
| Current status and perspective of tumor immunotherapy for head and neck squamous cell carcinoma. | Front Cell Dev Biol | 2022 | 36092724 | PubTator, text mining | PubMed |
| CXCL10-armed oncolytic adenovirus promotes tumor-infiltrating T-cell chemotaxis to enhance anti-PD-1 therapy. | Oncoimmunology | 2022 | 36092638 | PubTator, text mining | PubMed |
| Current clinical landscape of oncolytic viruses as novel cancer immunotherapeutic and recent preclinical advancements. | Front Immunol | 2022 | 36091031 | PubTator, text mining | PubMed |
| Small Nucleolar RNAs and Their Comprehensive Biological Functions in Hepatocellular Carcinoma. | Cells | 2022 | 36078062 | PubTator, text mining | PubMed |
| Application of bioreactor technology for cell culture-based viral vaccine production: Present status and future prospects. | Front Bioeng Biotechnol | 2022 | 36017347 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/6080/papers?page=9